Abstract
A wave of terminations of development programmes for cannabinoid receptor 1 blockers for obesity indicates the demise of a drug class that was once anticipated to yield blockbusters. Nevertheless, lessons learned might help salvage something for future such approaches.
MeSH terms
-
Anti-Obesity Agents / pharmacology
-
Anti-Obesity Agents / therapeutic use*
-
Cannabinoid Receptor Modulators / adverse effects
-
Cannabinoid Receptor Modulators / therapeutic use
-
Dexfenfluramine / adverse effects
-
Dexfenfluramine / therapeutic use
-
Eating / drug effects
-
Humans
-
Life Style
-
Obesity / drug therapy*
-
Obesity / physiopathology
-
Obesity / psychology
-
Piperidines / adverse effects
-
Piperidines / therapeutic use
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use
-
Receptor, Cannabinoid, CB1 / antagonists & inhibitors
-
Receptor, Cannabinoid, CB1 / drug effects*
-
Receptor, Cannabinoid, CB2 / antagonists & inhibitors
-
Receptor, Cannabinoid, CB2 / drug effects
-
Rimonabant
-
Risk Assessment
-
Risk Factors
Substances
-
Anti-Obesity Agents
-
Cannabinoid Receptor Modulators
-
Piperidines
-
Pyrazoles
-
Receptor, Cannabinoid, CB1
-
Receptor, Cannabinoid, CB2
-
Dexfenfluramine
-
Rimonabant